Las Virgenes Medical Clinic PRESENTs THE NeuroStar TMS Therapy® System - A Breakthrough Technology For The Treatment of Depression to enhance mental health
What are the benefits and risks of NeuroStar TMS Therapy?
NeuroStar TMS Therapy has been demonstrated to be safe and tolerable.
Over 10,000 active treatments were safely performed with NeuroStar TMS Therapy during the clinical trials.
- No side effects such as weight gain, sexual problems, stomach problems, sleepiness, or dry mouth were seen during trials
- There were no negative effects on memory or ability to concentrate
The most commonly reported side effect related to treatment was scalp pain or discomfort during the treatment session. This side effect was generally mild to moderate, and occurred less frequently after the first week of treatment. Less than 5% of patients treated with NeuroStar TMS Therapy discontinued treatment due to side effects.
NeuroStar TMS Therapy has been demonstrated to be effective in Major Depressive Disorder.
Efficacy was established in a controlled clinical trial comparing active treatment with the NeuroStar TMS Therapy system to an inactive device. Patients treated with active NeuroStar TMS Therapy experienced an average reduction in their depression symptom score of 22.1% compared to a 9% average reduction in patients receiving inactive treatment. NeuroStar-treated patients also experienced significant improvement in anxiety, appetite changes, aches and pains, and lack of energy associated with depression.
In an open label trial, which is most like a real world clinical practice, approximately 1 our of 2 patients treated with NeuroStar TMS Therapy experience significant improvement in depression symptoms, Approximately 1 out of 3 patients treated with Neurostar TMS Therapy experienced complete symptom relief at the end of 6 weeks. As with any antidepressant treatment, patients should be monitored for symptoms of worsening depression.
*NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.
- Thase M, Demitrack M, Evaluating Clinical Significance of Treatment Outcomes in Studies of Resistant Major Depression, Biological Psychiatry, April 1, 2008: Vol. 63:7s Page 138s.
- Janicak, Philip G., et al. Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: A Comprehensive Summary of Safety Experience From Acute Exposure, Extended Exposure, and During Reintroduction Treatment. Journal of Clinical Psychiatry, January 23, 2008.


